In response to the FDA’s recently published article outlining enhancements to Section 804 importation programs, AMPS supports the agency’s commitment to addressing the affordability crisis in prescription drugs. The FDA’s focus on simplifying importation proposals confirms what AMPS has long believed. Lowering drug costs starts with expanding access to safe and affordable medications.
With Drexi, the PBM solution from AMPS, access and savings are already in place. Drexi’s international sourcing program is fully operational, compliant, and currently delivering measurable savings to self-insured plans and their members. While states begin tackling the FDA’s updated framework, Drexi is already providing the type of access, transparency, and quality the agency is promoting.
Our program sources medications from Tier 1 countries, including Canada, the United Kingdom, Australia, and New Zealand. Every prescription is dispensed through licensed and credentialed pharmacies, meeting the highest standards of safety and efficacy. This is not a model in progress. It is a trusted and proven solution that is already making a difference.
In addition to international sourcing, Drexi also offers eligible clients access to the federal 340B program, unlocking another powerful savings opportunity. This is part of our broader commitment to delivering the lowest possible cost in high-quality prescription care, without compromising safety or the member experience.
The FDA’s announcement is a monumental step forward in federal policy. It reinforces the ever-increasing need for innovative and member-centric approaches to pharmacy benefits. Drexi is already delivering those results as part of the broader AMPS health care savings platform.
For self-insured employers, brokers, and TPAs who are ready to stop waiting on policy and start delivering real value, AMPS is your partner. With Drexi, you don’t have to wait for savings, clarity, or compliance. It’s fully built, actively delivering, and making a measurable impact where it matters most.
